BMC
PHAT icon

Bear Mountain Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Bear Mountain Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$14K – 283
2025
Q3 		$14K Hold
1,000
– – ﹤0.01% 95
2025
Q2 		$7.95K Hold
1,000
– – ﹤0.01% 108
2025
Q1 		$4.36K Hold
1,000
– – ﹤0.01% 124
2024
Q4 		$7.17K Hold
1,000
– – ﹤0.01% 97
2024
Q3 		$15.7K Hold
1,000
– – 0.01% 83
2024
Q2 		$11.7K Buy
1,000
+800
+400% +$8.24K ﹤0.01% 96
2024
Q1 		$1.96K Hold
200
– – ﹤0.01% 170
2023
Q4 		$1.5K Buy
+200
New +$1.72K ﹤0.01% 178

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bear Mountain Capital's PHAT Position: Q4 2025 in Review

Bear Mountain Capital sold out of Phathom Pharmaceuticals (PHAT) in Q4 2025, closing a stake of 1,000 shares — an estimated $14K sold.

Bear Mountain Capital first reported a position in PHAT in Q4 2023 and held it in 8 quarters. The position peaked at $15.7K in Q3 2024. 172 funds tracked by Wall St. Rank hold PHAT as of Q4 2025.

  • Bear Mountain Capital reported no remaining Phathom Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bear Mountain Capital sold 1,000 Phathom Pharmaceuticals shares in Q4 2025, an estimated $14K.
  • Bear Mountain Capital first reported a position in Phathom Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Bear Mountain Capital's Phathom Pharmaceuticals position peaked at $15.7K in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2025.

Based on Bear Mountain Capital's 13F filing for Q4 2025, filed 22 Jan 2026.